Spametrin-M en es it fr

Spametrin-M Brand names, Spametrin-M Analogs

Spametrin-M Brand Names Mixture

  • No information avaliable

Spametrin-M Chemical_Formula


Spametrin-M RX_link

Spametrin-M fda sheet

Spametrin-M msds (material safety sheet)

Spametrin-M MSDS

Spametrin-M Synthesis Reference

A. Stoll et al., eidem, Helv. Chim. Acta. 26, 944 (1943)

Spametrin-M Molecular Weight

339.432 g/mol

Spametrin-M Melting Point

172 oC

Spametrin-M H2O Solubility

25 mg/mL

Spametrin-M State


Spametrin-M LogP


Spametrin-M Dosage Forms

Injection (intramuscular or intravenous); Tablet

Spametrin-M Indication

For the prevention and control of excessive bleeding following vaginal childbirth

Spametrin-M Pharmacology

Methylergonovine is a semisynthetic ergot alkaloid and a derivative of ergonovine and is used for the prevention and control of postpartum and post-abortion hemorrhage. In general, the effects of all the ergot alkaloids appear to results from their actions as partial agonists or antagonists at adrenergic, dopaminergic, and tryptaminergic receptors. The spectrum of effects depends on the agent, dosage, species, tissue, and experimental or physiological conditions. All of the alkaloids of ergot significantly increase the motor activity of the uterus. After small doses contractions are increased in force or frequency, or both, but are followed by a normal degree of relaxation. As the dose is increased, contractions become more forceful and prolonged, resting tonus is markedly increased, and sustained contracture can result.

Spametrin-M Absorption

Absorption is rapid after oral (60% bioavailability) and intramuscular (78% bioavailability) administration.

Spametrin-M side effects and Toxicity

Signs and symptoms of overexposure: hypertension, seizures, headache, hypotension, nausea, and vomiting.

Spametrin-M Patient Information

Spametrin-M Organisms Affected

Humans and other mammals